Project Grant R41HL180185
Award Date 9/24/25
Completion Date 8/31/26
Dollars Obligated $509K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92130, USA
Similar Awards
- This Cooperative Agreement award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $576,303 to Duke University to develop "ORP100S", an engineered version of the human protein thioredoxin, as a therapeutic agent for mitigating radiation-induced injury. The 5-year project aims to further define the efficacy of ORP100S in protecting hematopoietic stem cells and other organ systems from lethal radiation doses, even when administered...
- This $431,750 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to examine the mitigating effects of the small molecule UTS-1401 on both hematopoietic acute radiation syndrome (H-ARS) and gastrointestinal acute radiation syndrome (GI-ARS) following whole body irradiation in Swiss mice. The researchers plan to administer UTS-1401 at various timepoints relative to radiation...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $219,024.00 to The University of Texas Health Science Center at Tyler to test the ability of the CSP7 peptide to inhibit radiation-induced lung injury (RILI) and resolve radiation-induced pulmonary fibrosis (RIPF) in mouse models. The award aims to develop a novel peptide intervention for cancer patients undergoing thoracic radiation therapy, which can lead to acute and chronic lung...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $155,857 Project Grant under the Trans-NIH Research Support (CFDA 93.310) program to Signablok, Inc. in Massachusetts. The funding supports the development of a novel medical countermeasure to mitigate potentially lethal acute radiation syndrome (ARS). The project aims to create a well-tolerable and effective first-in-class therapeutic that can be administered at least 24 hours post-radiation exposure...
- This federal Project Grant award of $155,500 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will support research at the University of Iowa to investigate the role of nitro-oxidative signaling and mitochondrial metabolism in mitigating age-associated, radiation-induced cardiopulmonary damage. The research will utilize genetically modified mice and an upper body irradiation model to elucidate the impact of nitric oxide synthase 1 (NOS1) disruption...
- The Project Grant titled "Engineered Microbes to Mitigate Intestinal Radiation Damage" was awarded by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $160,125 award to Baylor College of Medicine aims to explore the use of the microbiome to deliver growth factors that promote survival and proliferation of radioresistant intestinal stem cells. The objective is to assess a genetically...
- This $164,500 Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports the development and validation of human normal tissue patient-derived organoids (NT-PDOs) for pre-screening new candidate gastrointestinal (GI) radiation countermeasure drugs. The goal is to create an extracorporeal model based on healthy human GI tissue that can accurately assess the efficacy and safety of radiation mitigators, addressing limitations of...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $1,233,852.00 to Allander Biotechnologies, Inc. for the development of a proprietary oral gel treatment for radiation-induced oral mucositis in cancer patients. The primary goal of this first-in-human clinical trial is to assess the safety and feasibility of the drug, with a secondary objective of defining the optimal efficacy dosage. Allander Biotechnologies has completed...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $155,000 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the mitochondrial serine/threonine phosphatase PGAM5 as a potential target for mitigating gastrointestinal acute radiation syndrome (GI-ARS). The research aims to examine the role of PGAM5 in radiation-induced oxidative stress and modulation of Wnt/β-catenin...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $585,976 to Providence Health & Services - Oregon to conduct research on enhancing the efficacy of radiation therapy through spatially restricted anti-TGFβ treatment in the tumor microenvironment. The key objectives are to determine the role of self-renewing stem-like CD8+ T cells in local and distant radiation response, and to test radiation therapy combined with...